Data443 Launches Convaa.ai™ for Regulated Enterprises: Multi-Company AI Collaboration on Their Own Infrastructure, Under Their Own Control

Data443 Risk Mitigation, Inc. (ATDS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Data443 Launches Convaa.ai™ for Regulated Enterprises: Multi-Company AI Collaboration on Their Own Infrastructure, Under Their Own Control As frontier AI vendors and hyperscalers raise prices, retire models and step back from group AI, Convaa.ai™ gives CIOs, CISOs an

Original reporting
Published Oct 22, 2026, 1:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ATDS
Neutral
medium confidence
Mentioned
$ATDS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ATDSNeutralLow
01

Why it matters

The launch positions Data443 in a niche market of on‑prem AI, differentiating it from hyperscalers but facing adoption hurdles.

02

Market read

A new enterprise AI platform could modestly affect Data443's valuation; broader sector impact is limited.

03

What to watch

Potential regulatory scrutiny on AI data handling and the need for substantial integration effort by customers.

Relevance 6/10Novelty 6/10Timing: today

Background

Data443 Risk Mitigation, Inc. (OTC: ATDS) is a data security software firm expanding its portfolio with AI collaboration tools for regulated industries.

Company-level read

Ticker impact

$ATDSNeutralMedium confidence
Context

Data443 filed an 8‑K announcing the launch of Convaa.ai™, an enterprise AI collaboration platform for regulated firms.

Expected impact

potential modest upside as investors assess market demand for on‑prem AI solutions

Evidence & confidence

Product launch is a primary disclosure but lacks large‑scale financial metrics; impact depends on adoption rates.

Market effects

Highlights growing interest in on‑prem AI for regulated sectors, may spur competition among enterprise AI vendors.

Primarily U.S. and North American enterprise market; limited immediate global effect.

Modest, as the platform targets regulated enterprises worldwide.

Counterpoint

Adoption could be slower if larger cloud providers lower prices or improve data controls, limiting Data443's upside.

Key entities

  • Data443 Risk Mitigation, Inc.

    Provider of data security and privacy software launching Convaa.ai™.

Related articles

$ABCLMedAI 8/10

AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results

AbCellera Biologics (ABCL) plans to advance its hot-flash drug, ABCL635, into Phase 3 trials after promising Phase 2 results. The company is modeling dosing and engaging in regulatory discussions with the FDA. ABCL635 showed sleep-score results comparable to Bayer's LYNKUET, according to the company. AbCellera is also developing other candidates, including ABCL992, a longer-acting version of ABCL635.

$VANIMedAI 8/10

Vivani reports phase 1 trial results for semaglutide implant

Vivani Medical (NASDAQ:VANI) reported Phase 1 trial results for NPM-139, a semaglutide implant for weight management. The trial showed no adverse events in the NPM-139 group, with similar weight loss to Wegovy. Vivani plans to advance to Phase 2 trials in 2027 and explore development in new patient groups. The company collaborates with Novo Nordisk on the technology.

$ABUSMedAI 8/10

Arbutus Biopharma Updates Corporate Presentation, Reports $104.6M in Cash

Arbutus Biopharma updated its corporate presentation, reporting $104.6M in cash as of October 31, 2026. The company highlighted its hepatitis B pipeline, including 46% of Phase 2a patients achieving functional cure or discontinuing therapy, and plans for a potential Phase 2b imdusiran trial. AB-101 Phase 1 findings showed full PD-L1 receptor occupancy in 11 of 13 healthy subjects at 40 mg.